Subscribe to RSS

DOI: 10.5935/2526-8732.20210015
Immune and targeted therapy for cancer: time to rethink restrictions for the treatment of the elderly and frail
Terapia direcionada e imunológica para o câncer: hora de repensar as restrições para o tratamento de idosos e frágeis
Authors
Financial support: none to declare.

ABSTRACT
Targeted and immunotherapy have revolutionized cancer treatment. They safely substitute for traditional chemotherapy in a significant and growing number of malignancies. In this article, we review the United States Food and Drug Administration (FDA) - approved targeted and immunotherapies, currently used in oncology and compare their safety and efficacy in young versus geriatric and frail sub-population. The results suggest an overall comparable, if not superior efficacy in several tumor types, with acceptable toxicities across the board compared to cytotoxic chemotherapy and a favorable analysis in the comparison to the results observed in the younger population. The very decision to place elderly patients on exclusive palliative care can no longer be supported based on age or frailty alone. The historical concept of medical oncologists leaning for palliative treatments for these patients needs to be revisited.
RESUMO
A imunoterapia direcionada revolucionou o tratamento do câncer. Eles substituem com segurança a quimioterapia tradicional em um número significativo e crescente de doenças malignas. Neste artigo, revisamos a Food and Drug Administration (FDA) - imunoterapias direcionadas aprovadas atualmente usadas em oncologia, e comparamos sua segurança e eficácia na subpopulação jovem versus geriátrica e frágil. Com resultados sugerindo uma eficácia geral comparável, se não superior, em vários tipos de tumor com toxicidades aceitáveis em toda a linha em comparação com a quimioterapia citotóxica, e uma análise favorável na comparação com os resultados observados na população mais jovem. A própria decisão de colocar pacientes idosos em cuidados paliativos exclusivos não pode mais ser sustentada apenas com base na idade ou fragilidade. O conceito histórico de médicos oncologistas que buscam tratamentos paliativos para esses pacientes precisa ser revisitado.
CONFLICT OF INTEREST STATEMENT
The authors listed below certify that they have no involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships and affiliations) in the subject matter discussed in this manuscript.
Juliana Beal
Nothing to disclose.
Gustavo Schvartsman
Participation in speakers' bureaus: Bristol-Myers Squibb, Novartis, Merck Sharp and Dohme, Sanofi, AstraZeneca, Roche, Amgen. Consultancies: AstraZeneca, Roche, Merck Sharp and Dohme.
Rodrigo Munhoz
Honoraria: Bayer, BMS, Novartis, Merck-Serono, MSD, Roche, Sanofi. Participation in speakers' bureaus: BMS, Novartis, Merck-Serono, MSD, Roche, Sanofi. Consultancies: Bayer, Merck-Serono, Roche, Sanofi.
Theodora Karnakis Nothing to disclose.
Rafael Kaliks
Participation in speakers' bureaus: Astra Zeneca; Novartis; Pfizer; Roche. Consultancies: Astra Zeneca.
Publication History
Received: 10 March 2021
Accepted: 29 March 2021
Article published online:
18 July 2021
© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Juliana Rodrigues Beal, Gustavo Schvartsman, Rodrigo Ramella Munhoz, Theodora Karnakis, Rafael Aliosha Kaliks. Immune and targeted therapy for cancer: time to rethink restrictions for the treatment of the elderly and frail. Brazilian Journal of Oncology 2021; 17: e-20210015.
DOI: 10.5935/2526-8732.20210015
-
REFERENCES
-
White MC,
Holman DM,
Boehm JE,
Peipins LA,
Grossman M,
Henley SJ..
Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 2014; Mar;
46 (3 Suppl 1); S7-S15
Reference Ris Wihthout Link
-
Wildiers H,
Heeren P,
Puts M,
Topinkova E,
Janssen-Heijnen ML,
Extermann M.
et al
International Society of Geriatric Oncology consensus on geriatric assessment in older
patients with cancer. J Clin Oncol 2014; Aug; 32 (24) 2595-2603
Reference Ris Wihthout Link
-
Soto-Perez-de-Celis E,
Li D,
Yuan Y,
Lau YM,
Hurria A..
Functional versus chronological age: geriatric assessments to guide decision making
in older patients with cancer. Lancet Oncol 2018; Jun; 19 (06) e305-e16
Reference Ris Wihthout Link
-
Darvin P,
Toor SM,
Nair VS,
Elkord E..
Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med
2018; Dec; 50 (12) 1-11
Reference Ris Wihthout Link
-
Helissey C,
Vicier C,
Champiat S..
The development of immunotherapy in older adults: new treatments, new toxicities?.
J Geriatr Oncol 2016; Sep; 7 (05) 325-333
Reference Ris Wihthout Link
-
Hanahan D,
Weinberg RA..
Hallmarks of cancer: the next generation. Cell 2011; Mar; 144 (05) 646-674
Reference Ris Wihthout Link
-
Elias R,
Karantanos T,
Sira E,
Hartshorn KL..
Immunotherapy comes of age: immune aging & checkpoint inhibitors. J Geriatr Oncol
2017; May; 8 (03) 229-235
Reference Ris Wihthout Link
-
Finn RS,
Ryoo BY,
Merle P,
Kudo M,
Bouattour M,
Lim HY.
et al
Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma
in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020; 38
(03) 193-202
Reference Ris Wihthout Link
-
Ready N,
Hellmann MD,
Awad MM,
Otterson GA,
Gutierrez M,
Gainor JF.
et al
First-Line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate
568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers.
J Clin Oncol 2019; Apr; 37 (12) 992-1000
Reference Ris Wihthout Link
-
Mok TSK,
Wu YL,
Kudaba I,
Kowalski DM,
Cho BC,
Turna HZ.
et al
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally
advanced or metastatic non- smallcell lung cancer (KEYNOTE-042): a randomised, open-label,
controlled, phase 3 trial. Lancet 2019; 393 (10183): 1819-1830
Reference Ris Wihthout Link
-
Reck M,
Rodriguez-Abreu D,
Robinson AG,
Hui R,
Csoszi T,
Fulop A.
et al
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N
Engl J Med 2016; Nov; 375 (+19); 1823-1833
Reference Ris Wihthout Link
-
Elias R,
Morales J,
Rehman Y,
Khurshid H..
Immune checkpoint inhibitors in older adults. Curr Oncol Rep 2016; Aug; 18 (08) 47
Reference Ris Wihthout Link
-
Nishijima TF,
Muss HB,
Shachar SS,
Moschos SJ..
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and
older patients: a systematic review and meta- analysis. Cancer Treat Rev 2016; 45:
30-37
Reference Ris Wihthout Link
-
Bastholt L,
Schmidt H,
Bjerregaard JK,
Herrstedt J,
Svane IM..
Age favoured overall survival in a large population-based Danish patient cohort treated
with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. Eur J Cancer 2019;
Aug; 119: 122-131
Reference Ris Wihthout Link
-
Barlesi F,
Audigier-Valette C,
Felip E,
Ciuleanu T,
Jao K,
Rijavec E.
et al
OA04.02 CheckMate 817: first-line nivolumab + ipilimumab in patients with ECOG PS
2 and other special populations with advanced NSCLC. J Thorac Oncol 2019; Oct; 14
(10) S214-S5
Reference Ris Wihthout Link
-
Middleton G,
Brock K,
Savage J,
Mant R,
Summers Y,
Connibear J.
et al
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2
(PePS2): a single arm, phase 2 trial. Lancet Respir Med 2020; Sep; 8 (09) 895-904
Reference Ris Wihthout Link
-
Balar AV,
Castellano D,
O'Donnell PH,
Grivas P,
Vuky J,
Powles T.
et al
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and
unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm,
phase 2 study. Lancet Oncol 2017; Nov; 18 (11) 1483-1492
Reference Ris Wihthout Link
-
Spigel DR,
McCleod M,
Jotte RM,
Einhorn L,
Horn L,
Waterhouse DM.
et al
Safety, efficacy, and patient-reported health-related quality of life and symptom
burden with nivolumab in patients with advanced non-small cell lung cancer, including
patients aged 70 years or older or with poor performance status (CheckMate 153). J
Thorac Oncol 2019; Sep; 14 (09) 1628-1639
Reference Ris Wihthout Link
-
Sbrana A,
Antognoli R,
Pasqualetti G,
Linsalata G,
Okoye C,
Calsolaro V.
et al
Effectiveness of multi-prognostic index in older patients with advanced malignancies
treated with immunotherapy. J Geriatr Oncol 2020; Apr; 11 (03) 503-507
Reference Ris Wihthout Link
-
Joensuu H,
Roberts PJ,
Sarlomo-Rikala M,
Andersson LC,
Tervahartiala P,
Tuveson D.
et al
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal
stromal tumor. N Engl J Med 2001; Apr; 344 (14) 1052-1056
Reference Ris Wihthout Link
-
Garraway LA..
Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013; May;
31 (15) 1806-1814
Reference Ris Wihthout Link
-
Zehir A,
Benayed R,
Shah RH,
Syed A,
Middha S,
Kim HR.
et al
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing
of 10,000 patients. Nat Med 2017; Jun; 23 (06) 703-713
Reference Ris Wihthout Link
-
Drilon A,
Laetsch TW,
Kummar S,
DuBois SG,
Lassen UN,
Demetri GD.
et al
Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N
Engl J Med 2018; Feb; 378 (08) 731-739
Reference Ris Wihthout Link
-
Suidan AM,
Roisman L,
Rozenblum AB,
Ilbouze M,
Dudnik E,
Zer A.
et al
Lung cancer in young patients: higher rate of driver mutations and brain involvement,
but better survival. J Glob Oncol 2019; May; 5: 1-8
Reference Ris Wihthout Link
-
Cancer Genome Atlas Network.
Genomic classification of cutaneous melanoma. Cell 2015; Jun; 161 (07) 1681-1696
Reference Ris Wihthout Link
-
Hutson TE,
Bukowski RM,
Rini BI,
Gore ME,
Larkin JM,
Figlin RA.
et al
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.
Br J Cancer 2014; Mar; 110 (05) 1125-1132
Reference Ris Wihthout Link
-
Brunello A,
Basso U,
Sacco C,
Sava T,
Vivo R,
Camerini A.
et al
Safety and activity of sunitinib in elderly patients (>70 years) with metastatic renal
cell carcinoma: a multicenter study. Ann Oncol 2013; Feb; 24 (02) 336-342
Reference Ris Wihthout Link
-
Eisen T,
Oudard S,
Szczylik C,
Gravis G,
Heinzer H,
Middleton R.
et al
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized
trial. J Natl Cancer Inst 2008; Oct; 100 (20) 1454-1463
Reference Ris Wihthout Link
-
Rini BI,
Escudier B,
Tomczak P,
Kaprin A,
Szczylik C,
Hutson TE.
et al
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma
(AXIS): a randomised phase 3 trial. Lancet 2011; Nov; 378 (9807) 1931-1939
Reference Ris Wihthout Link
-
Merimsky O,
Cheng CK,
Au JS,
Von Pawel J,
Reck M..
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small
cell lung cancer. Oncol Rep 2012; Aug; 28 (02) 721-727
Reference Ris Wihthout Link
-
Wheatley-Price P,
Ding K,
Seymour L,
Clark GM,
Sheperd FA..
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the
National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol
2008; May; 26 (14) 2350-2357
Reference Ris Wihthout Link
-
Bedas A,
Peled N,
Rabinovich NM,
Mishaeli M,
Schochat T,
Zer A.
et al
Efficacy and safety of ALK tyrosine kinase inhibitors in elderly patients with advanced
alk-positive non-small cell lung cancer: findings from the real-life cohort. Oncol
Res Treat 2019; 42 (05) 275-282
Reference Ris Wihthout Link
-
Ascierto PA,
McArthur GA,
Dréno B,
Atkinson V,
Liszkay G,
Di Giacomo AM.
et al
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM):
updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol
2016; Sep; 17 (09) 1248-1260
Reference Ris Wihthout Link
-
Robert C,
Grob JJ,
Stroyakovskiy D,
Karaszewska B,
Hauschild A,
Levchenko E.
et al
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl
J Med 2019; Aug; 381 (07) 626-636
Reference Ris Wihthout Link
-
Daste A,
Chakiba C,
Domblides C,
Gross-Goupil M,
Quivy A,
Ravaud A.
et al
Targeted therapy and elderly people: a review. Eur J Cancer 2016; Dec; 69: 199-215
Reference Ris Wihthout Link
-
Hurria A,
Dale W,
Mooney M,
Rowland JH,
Ballman KV,
Cohen HJ.
et al
Designing therapeutic clinical trials for older and frail adults with cancer: U13
conference recommendations. J Clin Oncol 2014; Aug; 32 (24) 2587-2594
Reference Ris Wihthout Link
-
Lewis JH,
Kilgore ML,
Goldman DP,
Trimble EL,
Kaplan R,
Montello MJ.
et al
Participation of patients 65 years of age or older in cancer clinical trials. J Clin
Oncol 2003; Apr; 21 (07) 1383-1389
Reference Ris Wihthout Link
-
Howlader N NA,
Krapcho M,
Miller D,
Brest A,
Yu M,
Ruhl J,
Tatalovich Z,
Mariotto A,
Lewis DR,
Chen HS,
Feuer EJ,
Cronin KA.
Surveillance, epidemiology, and end results (SEER) Program SEER*Stat Database: Mortality
- Total U.S. (1969-2016). Bethesda: National Cancer Institute (NIH);; 2019
Reference Ris Wihthout Link
-
Wildiers H,
Mauer M,
Pallis A,
Hurria A,
Mohile SG,
Luciani A.
et al
End points and trial design in geriatric oncology research: a joint European organisation
for research and treatment of cancer-- Alliance for Clinical Trials in Oncology--International
Society Of Geriatric Oncology position article. J Clin Oncol 2013; Oct; 31 (29) 3711-3718
Reference Ris Wihthout Link
-
Soubeyran P,
Bellera C,
Goyard J,
Heitz D,
Cure H,
Rousselot H.
et al
Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter
cohort study. PLoS One 2014; Dec; 9 (12) e115060
Reference Ris Wihthout Link
-
Owusu C,
Koroukian SM,
Schluchter M,
Bakaki P,
Berger NA..
Screening older cancer patients for a comprehensive geriatric assessment: a comparison
of three instruments. J Geriatr Oncol 2011; Apr; 2 (02) 121-129
Reference Ris Wihthout Link
-
Luo J,
Rizvi H,
Egger JV,
Preeshagul IR,
Wolchok JD,
Hellman MD..
Impact of PD-1 blockade on severity of COVID19 in patients with lung cancers. Cancer
Discovery 2020; May; 12; Epub ahead of print.
Reference Ris Wihthout Link